Improved Diagnosis of Ovarian Cancer

NCT ID: NCT05842629

Last Updated: 2024-05-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-15

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After implementation of systematic image description of adnexal masses, we aim to improve and evaluate our use of available imaging methods and biomarkers for classifying adnexal masses and distinguishing between benign and malignant adnexal masses in the hands of clinicians in Central Denmark Region.

Secondarily, we want to improve our management of adnexal masses by evaluating the complications and longitudinal changes in conservatively managed adnexal masses.

Data is registered prospectively but analyzed retrospectively.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Imaging methods include ultrasonography (US) by varied observers, Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computed Tomography (PET-CT).

Imaging criteria are based on recommendations by the International Ovarian Tumor Analysis (IOTA) group. Educational efforts in IOTA terminology and systematic description at ultrasonography may support quality in the diagnostic process.

Patients will be diagnosed and treated according to national and regional guidelines by the local clinicians.

The project has been evaluated by the Ethical Committee in the Central Denmark Region prior to initiation.

The aim of the power calculation for estimation of sample size is to be able to detect a difference in sensitivity from 75% to 90% at a threshold of 200 for Risk of Malignancy Index (RMI) and 10% for Assessment of Different NEoplasia of the adneXa (ADNEX) model and two-step-strategy / The Ovarian-Adnexal Reporting and Data System (O-RADS). To detect a difference in sensitivity (90% for ADNEX and two-step-strategy vs 75% for RMI at a specificity of 80%) at least 103 cases of malignancy should be included (calculated by using paired proportions).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Neoplasms Ovarian Cancer Ovarian Cysts Adnexal Mass Adnexal Lesion Adnexal Carcinoma Adnexal Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with an adnexal lesion in the Central Denmark Region

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with an adnexal mass observed at ultrasonography.
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aarhus University Hospital

OTHER

Sponsor Role collaborator

Regionshospitalet Horsens

OTHER

Sponsor Role collaborator

Department of Gynaecology and Obstetrics, Viborg Regional Hospital

UNKNOWN

Sponsor Role collaborator

Department of Gynaecology and Obstetrics, Goedstrup Regional Hospital

UNKNOWN

Sponsor Role collaborator

Department of Gynaecology and Obstetrics, Randers Regional Hospital

UNKNOWN

Sponsor Role collaborator

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ina Marie Dueholm Hjorth

Medical Doctor, PhD-student

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ina Marie Dueholm Hjorth, MD

Role: PRINCIPAL_INVESTIGATOR

University of Aarhus

Ole Mogensen, DMSci

Role: STUDY_DIRECTOR

University of Aarhus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Gynaecology and Obstetrics, Aarhus University Hospital

Aarhus, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ina Marie Dueholm Hjorth, MD

Role: CONTACT

+004526192456

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ina Marie Dueholm Hjorth, MD

Role: primary

+45 26192456

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

adnexproject

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.